Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8: early-phase trial registry
2 of 6 indexed Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8: 6 US clinical trials tracked, 2 recruiting.
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is NRG Oncology, running 2 of these trials.
Enrollment posture brief
Registry condition clinical-stage-ii-gastroesophageal-junction-adenocarcinoma-ajcc-v8
OPEN 2 | RECR 33% | LATE 1 | EARLY 5 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 research.
NRG Oncology accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 99 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
NCT03801876
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
Mayo Clinic
NCT06078709
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
National Cancer Institute (NCI)
NCT05836584
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
NCT03784326
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
NCT04391049
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
NCT04929392
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NRG Oncology sponsors the most Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See NRG Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 condition card totals 6 registered trials; most-linked intervention Computed Tomography; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.